TRAIL/Apo-2L: mechanisms and clinical applications in cancer. - Wikidata - awgldk - TriplyDB

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

http://www.wikidata.org/entity/Q34482821

about

Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2 HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis Marine Carotenoids against Oxidative Stress: Effects on Human Health Plant sterols as anticancer nutrients: evidence for their role in breast cancer Siphonaxanthin, a green algal carotenoid, as a novel functional compound Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5 Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells.Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo Fasting enhances TRAIL-mediated liver natural killer cell activity via HSP70 upregulation Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway.The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells.Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.Regulation of apoptosis proteins in cancer cells by ubiquitin.Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte.Multiple mechanisms of immune suppression by B lymphocytes Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells.Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential.Proteomics to display tissue repair opposing injury response to LPS-induced liver injury.Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis.Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma.Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis Combined Treatment of Androgen-Independent Prostate Cancer Cell Line DU145 with Chemotherapeutic Agents and Lithium Chloride: Effect on Growth Arrest and/or Apoptosis (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-κB and up-regulation of TNFRSF10B (DR5).The synergistic apoptotic interaction of Indole-3-Carbinol and Genistein with TRAIL on endometrial cancer cells.Molecular targeted therapies for pancreatic cancer.

P2860

Q21133690-78BC1D7A-0744-4107-B21F-FAB435BC1311 Q24650617-2A30A5D0-AB40-4F0A-BC8A-5F33B911CA37 Q24798681-775775DA-443F-427F-AA51-B7A7DE5186BB Q26782061-0A5E7971-12B1-49C3-854F-A5C5ABF0304B Q26861053-24FC0C68-2146-41DD-8CDE-E5E7B90A3376 Q26862953-CEA8BB70-9069-4D66-A57D-06CDE7531BA4 Q27472970-4CE3FB3B-8A3F-4D68-861C-19261E33D017 Q28548386-DB61A2EA-F713-4B5E-BE73-21958F88BC43 Q28565846-574F87DD-8DD5-4234-AD00-43AC8B95ACDD Q30851343-F6271972-6B2F-423C-8A99-5F9465D6E16A Q30994649-8034734A-6EAD-451F-A71D-D2D56461AFDC Q33685962-AEB1B3A0-7A13-41E9-B9EA-E016CDE2DA26 Q33862991-08E7D95A-FD91-4BCD-ABB8-C37A5F6D5695 Q34053698-9119EA2A-BCF1-45C0-AB01-BD1BDC69C3E3 Q34105402-7FEFB34D-009B-439F-8319-8DE9559246A2 Q34129830-D6294BAD-94E8-4509-8EE3-B7D9AD87A850 Q34256933-E3158127-1DC0-4F5D-B359-3A7B577F3948 Q34428370-ED4D28D8-6E21-4CDA-B804-49A590485E7B Q34534169-77417C3F-493A-4275-BD79-47D395337CB4 Q34610496-F2638A69-1145-48AB-9DB2-AE7C534E398F Q34734032-B0E9AF88-BC5B-470B-90A1-9A968BA90EE7 Q34865077-68833F87-2558-44F0-A5E0-CCB273E5E1EE Q35103344-3A3618E0-7E19-41FC-B64C-016EB1AB4424 Q35138276-9FB2EAB7-7628-4F4D-9FA0-F93E594482C4 Q35691538-81BD2107-9412-4C60-9580-E13A021EA677 Q35744028-2C0D6AD4-F213-4F0E-BC17-B3109AF1E200 Q35747533-C64C6E9B-6842-428A-AFBB-148B8C891A45 Q35955377-F96E779F-BAAD-4BF6-B6F0-D368DA54D88B Q36059686-AA0ADA3C-27BF-4923-9511-9A143155B388 Q36065802-CD76F7A3-29E1-448B-9F49-31454D7F26AD Q36151210-42062829-9E49-4DB0-A0AC-DBD2577CE6AC Q36261259-086EDB79-8BD7-4454-AA5A-0F47E15713B6 Q36335972-BDCA6A5B-A3B8-4A5A-9074-38D74B59222B Q36344857-607F93B2-600D-434F-A37B-16CAF7145DF6 Q36423258-CB57E4D7-25B3-4E8D-8315-0BBE11E05962 Q36473635-3DA71CC4-AEDE-44AB-8EB7-78A7116EF035 Q36571446-7A7EDBDF-AC6A-4D4A-9687-C59FC564F7C2 Q36681789-212415DD-44F8-45C3-BCC6-4CAB6527772E Q36742314-DDD3AD8A-DC82-43AC-9FE9-F3D6DA22D81B Q36944441-ED9B5503-6DCD-493B-90FD-CB8DE08233F0

P2860

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

http://www.wikidata.org/entity/Q34482821

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@ast

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@en

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@nl

type

label

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@ast

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@en

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@nl

prefLabel

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@ast

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@en

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@nl

P1433

Q34482821-79234ACF-C338-4602-93D5-9113EEC4E551

P1476

Q34482821-1B5EB481-1860-4847-A475-167B2067E7F8

P2093

Q34482821-26CAE611-8334-4F23-8F56-E02F1A0033AB

P2860

Q34482821-008C3352-9A53-4A08-B056-D7509D059734

Q34482821-0144E2F9-1346-4F62-9F55-8C2EEDF68449

Q34482821-01A46523-045E-4B3D-AD21-55829B67EA02

Q34482821-036EB065-058E-4C7E-A8CB-25636A9A59A1

Q34482821-04A1AD85-89DB-4CEC-AE17-4A8CF1D0D1C2

Q34482821-05873CCF-7628-43E7-A5A1-0F2A3BA8F7CC

Q34482821-0A6AA981-5874-4058-BADB-1524032CDC4F

Q34482821-0BD62E83-3DCB-40BF-8FFC-6A30EE203E08

Q34482821-0BEFDAEE-6F1C-46B0-831D-226400A4F628

Q34482821-0BF38739-B413-4CEF-AA12-029E714B6260

P304

Q34482821-2D66685C-3B4D-422B-B503-1F8700E13D8F

P31

Q34482821-D7003391-5036-40CE-9135-F5B27B939BB4

P356

Q34482821-61BAA081-E792-4707-80EA-493B5F024322

P433

Q34482821-2EAADF80-3C9C-4326-8394-9072494AE855

P478

Q34482821-8682A29D-BF64-4FEA-A3FA-09DD90B8B6FB

P577

Q34482821-56E73A04-D069-4E4E-98B6-9F8BC0D7C329

P5875

Q34482821-58A6FD70-361F-4B70-A591-D5786A160B35

P698

Q34482821-1D5F44CC-0EB5-4E82-AAD8-0F1144E5E6AB

P932

Q34482821-CFA91A3F-24AD-464E-AAA6-EBFD0D4EB924

P356

P1433

P1476

TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

@en

P2093

R K Srivastava

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of mitochondrial apoptosis-inducing factor

Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II

Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule

Characterization of two receptors for TRAIL

The receptor for the cytotoxic ligand TRAIL

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

P304

535-546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NEO.7900203

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

252489159

http://www.w3.org/2001/XMLSchema#string

P698

11774036

http://www.w3.org/2001/XMLSchema#string

P932

1506567

http://www.w3.org/2001/XMLSchema#string